BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16428244)

  • 1. On prejudice and facts and choices.
    Köhne CH; Folprecht G
    Ann Oncol; 2006 Feb; 17(2):185-7. PubMed ID: 16428244
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.
    Mayer RJ
    J Clin Oncol; 2001 Nov; 19(21):4093-6. PubMed ID: 11689576
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
    Twelves C; Gollins S; Grieve R; Samuel L
    Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer.
    Gambill BD
    Clin Colorectal Cancer; 2001 May; 1(1):18-9. PubMed ID: 12445375
    [No Abstract]   [Full Text] [Related]  

  • 5. [Capecitabine in colorectal carcinoma: news from ASCO 2008]].
    Longo F; Mansueto G
    Tumori; 2008; 94(4):suppl 15-23. PubMed ID: 18822712
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in dukes C colon cancer: results from the X-ACT trial.
    Reddy GK
    Clin Colorectal Cancer; 2004 Jul; 4(2):87-8. PubMed ID: 15285814
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
    Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ASCO Annual Meeting 2004, New Orleans. Capecitabine in adjuvant therapy of colorectal carcinoma: first... the evidence].
    Longo F; Mansueto G
    Tumori; 2004; 90(5):14-21. PubMed ID: 15656348
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    Van Cutsem E; Hoff PM; Harper P; Bukowski RM; Cunningham D; Dufour P; Graeven U; Lokich J; Madajewicz S; Maroun JA; Marshall JL; Mitchell EP; Perez-Manga G; Rougier P; Schmiegel W; Schoelmerich J; Sobrero A; Schilsky RL
    Br J Cancer; 2004 Mar; 90(6):1190-7. PubMed ID: 15026800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Iqbal S; Lenz HJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
    Hochster HS
    Clin Adv Hematol Oncol; 2005 May; 3(5):405-6. PubMed ID: 16167014
    [No Abstract]   [Full Text] [Related]  

  • 12. 'Hold the Mayo': solid facts or pulp fiction?
    Punt CJ
    Ann Oncol; 2000 Aug; 11(8):919-20. PubMed ID: 11038025
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oral fluoropyrimidines in the treatment of colorectal carcinoma].
    Porschen R
    Dtsch Med Wochenschr; 2003 Jun; 128 Suppl 2():S121-3. PubMed ID: 12817344
    [No Abstract]   [Full Text] [Related]  

  • 15. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Mayer RJ
    J Clin Oncol; 2007 Sep; 25(27):4165-7. PubMed ID: 17709796
    [No Abstract]   [Full Text] [Related]  

  • 16. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
    Saif MW
    Clin Colorectal Cancer; 2005 Jul; 5(2):89-100. PubMed ID: 16098249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral fluoropyrimidines in colorectal cancer.
    Van Cutsem E; Peeters M
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):91-5. PubMed ID: 11049039
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer.
    Lamberti C; Sauerbruch T; Glasmacher A
    Cancer Treat Rev; 2005 Dec; 31(8):648-52. PubMed ID: 16289340
    [No Abstract]   [Full Text] [Related]  

  • 19. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer.
    Pfeiffer P; Mortensen JP; Bjerregaard B; Eckhoff L; Schønnemann K; Sandberg E; Aabo K; Jakobsen A
    Eur J Cancer; 2006 Nov; 42(16):2738-43. PubMed ID: 17011184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.